Molecular Oncology Diagnostics Market Size, Share, Scope, Forecast Report 2026 to 2035
Segmentations of Molecular Oncology Diagnostics Market :
Molecular Oncology Diagnostics Market by Product -
- Kits and Assays
- Instruments
- Software
Molecular Oncology Diagnostics Market by Technology -
- Polymerase Chain Reaction
- Next-Generation Sequencing
- Immunohistochemistry
- Fluorescence In-Situ Hybridization
- Flow Cytometry
- Other Technologies
Molecular Oncology Diagnostics Market by Application -
- Clinical Diagnostics
- Research Use
Molecular Oncology Diagnostics Market by Cancer Type -
- Solid Tumors
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Ovarian Cancer
- Other Solid Tumors
- Hematological Malignancies
- Lymphoma
- Leukemia
- Multiple Myeloma
- Other Hematological Malignancies
Molecular Oncology Diagnostics Market by End User -
- Hospitals and Diagnostic Centers
- Reference Laboratories
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
Molecular Oncology Diagnostics Market by Region-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Molecular Oncology Diagnostics Market Snapshot
Chapter 4. Global Molecular Oncology Diagnostics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Market Trends
4.5. Regulatory Landscape
4.6. Reimbursement Scenario Analysis
4.7. Porter’s Five Forces Analysis
4.8. Incremental Opportunity Analysis (US$ Mn), 2025–2035
4.9. Market Penetration & Growth Prospect Mapping (US$ Mn), 2026–2035
4.10. Competitive Landscape & Market Share Analysis, 2026
4.11. Impact of Precision Medicine and Companion Diagnostics on Market Growth
Chapter 5. Market Segmentation 1: By Product
5.1. Market Share, 2025 & 2035
5.2. Market Size (US$ Mn), 2022–2035
5.2.1. Kits and Assays
5.2.2. Instruments
5.2.3. Software
Chapter 6. Market Segmentation 2: By Technology
6.1. Market Share, 2025 & 2035
6.2. Market Size (US$ Mn), 2022–2035
6.2.1. Polymerase Chain Reaction (PCR)
6.2.2. Next-Generation Sequencing (NGS)
6.2.3. Immunohistochemistry (IHC)
6.2.4. Fluorescence In-Situ Hybridization (FISH)
6.2.5. Flow Cytometry
6.2.6. Other Technologies
Chapter 7. Market Segmentation 3: By Application
7.1. Market Share, 2025 & 2035
7.2. Market Size (US$ Mn), 2022–2035
7.2.1. Clinical Diagnostics
7.2.2. Research Use
Chapter 8. Market Segmentation 4: By Cancer Type
8.1. Market Share, 2025 & 2035
8.2. Market Size (US$ Mn), 2022–2035
8.2.1. Solid Tumors
8.2.2.1 Breast Cancer
8.2.1.2 Lung Cancer
8.2.1.3 Colorectal Cancer
8.2.1.4 Prostate Cancer
8.2.1.5 Ovarian Cancer
8.2.1.6 Other Solid Tumors
8.2.2. Hematologic Malignancies
8.2.2.1 Lymphoma
8.2.2.2 Leukemia
8.2.2.3 Multiple Myeloma
8.2.2.4 Other Hematological Malignancies
Chapter 9. Market Segmentation 5: By End User
9.1. Market Share, 2025 & 2035
9.2. Market Size (US$ Mn), 2022–2035
9.2.1. Hospitals and Diagnostic Centers
9.2.2. Reference Laboratories
9.2.3. Pharmaceutical and Biotechnology Companies
9.2.4. Academic and Research Institutes
Chapter 10. Regional Market Estimates & Trend Analysis
10.1. Global Market Regional Snapshot, 2025 & 2035
10.2. North America
10.2.1. Market Revenue by Country (U.S., Canada, Mexico), 2022–2035
10.2.2. North America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Product, 2022–2035
10.2.3. North America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Technology, 2022–2035
10.2.4. North America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Application, 2022–2035
10.2.5. North America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Cancer Type, 2022–2035
10.2.6. North America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By End User, 2022–2035
10.3. Europe
10.3.1. Market Revenue by Country, 2022–2035
10.3.2. Europe Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Product, 2022–2035
10.3.3. Europe Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Technology, 2022–2035
10.3.4. Europe Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Application, 2022–2035
10.3.5. Europe Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Cancer Type, 2022–2035
10.3.6. Europe Molecular Oncology Diagnostics Market Revenue (US$ Mn) By End User, 2022–2035
10.4. Asia Pacific
10.4.1. Market Revenue by Country, 2022–2035
10.4.2. Asia Pacific Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Product, 2022–2035
10.4.3. Asia Pacific Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Technology, 2022–2035
10.4.4. Asia Pacific Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Application, 2022–2035
10.4.5. Asia Pacific Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Cancer Type, 2022–2035
10.4.6. Asia Pacific Molecular Oncology Diagnostics Market Revenue (US$ Mn) By End User, 2022–2035
10.5. Latin America
10.5.1. Market Revenue by Country, 2022–2035
10.5.2. Latin America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Product, 2022–2035
10.5.3. Latin America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Technology, 2022–2035
10.5.4. Latin America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Application, 2022–2035
10.5.5. Latin America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Cancer Type, 2022–2035
10.5.6. Latin America Molecular Oncology Diagnostics Market Revenue (US$ Mn) By End User, 2022–2035
10.6. Middle East & Africa
10.6.1. Market Revenue by Country, 2022–2035
10.6.2. Middle East & Africa Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Product, 2022–2035
10.6.3. Middle East & Africa Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Technology, 2022–2035
10.6.4. Middle East & Africa Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Application, 2022–2035
10.6.5. Middle East & Africa Molecular Oncology Diagnostics Market Revenue (US$ Mn) By Cancer Type, 2022–2035
10.6.6. Middle East & Africa Molecular Oncology Diagnostics Market Revenue (US$ Mn) By End User, 2022–2035
Chapter 11. Competitive Landscape
11.1. Key Strategic Developments (M&A, Partnerships, Product Launches)
11.2. Market Share Analysis, 2026
11.3. Company Profiles (16 Players)
11.3.1. Abbott Laboratories
11.3.2. Agilent Technologies, Inc.
11.3.3. Biocartis Group NV
11.3.4. bioMérieux
11.3.5. Bio-Rad Laboratories, Inc.
11.3.6. Danaher Corporation
11.3.7. Exact Sciences Corporation
11.3.8. F. Hoffmann-La Roche Ltd.
11.3.9. Guardant Health, Inc.
11.3.10. Hologic, Inc.
11.3.11. Illumina, Inc.
11.3.12. Invivoscribe, Inc.
11.3.13. Myriad Genetics, Inc.
11.3.14. QIAGEN N.V.
11.3.15. Sysmex Corporation
11.3.16. Thermo Fisher Scientific, Inc.
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Molecular Oncology Diagnostics Market Size is valued at USD 2.60 Bn in 2025 and is predicted to reach USD 6.88 Bn by the year 2035
The Molecular Oncology Diagnostics Market is expected to grow at a 10.5% CAGR during the forecast period for 2026 to 2035
Abbott Laboratories, Agilent Technologies, Inc., Biocartis Group NV, bioMérieux, Bio-Rad Laboratories, Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Guardant Health, Inc., Hologic, Inc. and Others.
Molecular Oncology Diagnostics Market is segmented into Product, Technology, Application, Cancer Type, End User and Other.
North America region is leading the Molecular Oncology Diagnostics Market.